MERSANA THERAPEUTICS INC (MRSN)

US59045L1061 - Common Stock

0.72  -0.58 (-44.62%)

After market: 0.7015 -0.02 (-2.57%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MRSN. MRSN was compared to 561 industry peers in the Biotechnology industry. MRSN has a bad profitability rating. Also its financial health evaluation is rather negative. MRSN is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

MRSN had negative earnings in the past year.
In the past year MRSN has reported a negative cash flow from operations.
In the past 5 years MRSN always reported negative net income.
MRSN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -44.02%, MRSN perfoms like the industry average, outperforming 52.07% of the companies in the same industry.
MRSN's Return On Equity of -7113.35% is on the low side compared to the rest of the industry. MRSN is outperformed by 84.68% of its industry peers.
Industry RankSector Rank
ROA -44.02%
ROE -7113.35%
ROIC N/A
ROA(3y)-73.18%
ROA(5y)-55.6%
ROE(3y)-275.55%
ROE(5y)-180.25%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

MRSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRSN has been increased compared to 1 year ago.
MRSN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MRSN has a worse debt to assets ratio.

2.2 Solvency

MRSN has an Altman-Z score of -7.43. This is a bad value and indicates that MRSN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MRSN (-7.43) is worse than 69.55% of its industry peers.
A Debt/Equity ratio of 13.35 is on the high side and indicates that MRSN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 13.35, MRSN is doing worse than 84.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 13.35
Debt/FCF N/A
Altman-Z -7.43
ROIC/WACCN/A
WACC11.74%

2.3 Liquidity

MRSN has a Current Ratio of 2.35. This indicates that MRSN is financially healthy and has no problem in meeting its short term obligations.
MRSN has a Current ratio of 2.35. This is in the lower half of the industry: MRSN underperforms 72.61% of its industry peers.
A Quick Ratio of 2.35 indicates that MRSN has no problem at all paying its short term obligations.
MRSN's Quick ratio of 2.35 is on the low side compared to the rest of the industry. MRSN is outperformed by 71.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.35

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.12% over the past year.
MRSN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.70%.
MRSN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.33% yearly.
EPS 1Y (TTM)64.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)-14.7%
Revenue growth 3Y254.11%
Revenue growth 5Y28.33%
Sales Q2Q%63.65%

3.2 Future

MRSN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.28% yearly.
The Revenue is expected to grow by 35.09% on average over the next years. This is a very strong growth
EPS Next Y56.74%
EPS Next 2Y25.93%
EPS Next 3Y14.28%
EPS Next 5Y12.28%
Revenue Next Year-22.41%
Revenue Next 2Y-18.45%
Revenue Next 3Y5.86%
Revenue Next 5Y35.09%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRSN. In the last year negative earnings were reported.
Also next year MRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MRSN's earnings are expected to grow with 14.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.93%
EPS Next 3Y14.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRSN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERSANA THERAPEUTICS INC

NASDAQ:MRSN (1/10/2025, 7:26:17 PM)

After market: 0.7015 -0.02 (-2.57%)

0.72

-0.58 (-44.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners94.28%
Inst Owner Change0%
Ins Owners1.36%
Ins Owner Change0.66%
Market Cap83.27M
Analysts85
Price Target6.63 (820.83%)
Short Float %7.32%
Short Ratio7.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.67%
Min EPS beat(2)-14.37%
Max EPS beat(2)49.71%
EPS beat(4)3
Avg EPS beat(4)13.3%
Min EPS beat(4)-14.37%
Max EPS beat(4)49.71%
EPS beat(8)5
Avg EPS beat(8)9.15%
EPS beat(12)6
Avg EPS beat(12)-48.02%
EPS beat(16)6
Avg EPS beat(16)-40.62%
Revenue beat(2)1
Avg Revenue beat(2)-5.1%
Min Revenue beat(2)-74.22%
Max Revenue beat(2)64.02%
Revenue beat(4)2
Avg Revenue beat(4)-8.14%
Min Revenue beat(4)-74.22%
Max Revenue beat(4)64.02%
Revenue beat(8)2
Avg Revenue beat(8)-16.89%
Revenue beat(12)4
Avg Revenue beat(12)-3.11%
Revenue beat(16)4
Avg Revenue beat(16)-25.75%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17%
EPS NY rev (1m)0%
EPS NY rev (3m)15.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.39
P/FCF N/A
P/OCF N/A
P/B 79.38
P/tB 79.38
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0.3
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.02%
ROE -7113.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.18%
ROA(5y)-55.6%
ROE(3y)-275.55%
ROE(5y)-180.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 13.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.04%
Cap/Sales 1.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 2.35
Altman-Z -7.43
F-Score4
WACC11.74%
ROIC/WACCN/A
Cap/Depr(3y)151.69%
Cap/Depr(5y)110.08%
Cap/Sales(3y)546.39%
Cap/Sales(5y)339.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y56.74%
EPS Next 2Y25.93%
EPS Next 3Y14.28%
EPS Next 5Y12.28%
Revenue 1Y (TTM)-14.7%
Revenue growth 3Y254.11%
Revenue growth 5Y28.33%
Sales Q2Q%63.65%
Revenue Next Year-22.41%
Revenue Next 2Y-18.45%
Revenue Next 3Y5.86%
Revenue Next 5Y35.09%
EBIT growth 1Y59.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.27%
EBIT Next 3Y14.2%
EBIT Next 5YN/A
FCF growth 1Y-127.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.52%
OCF growth 3YN/A
OCF growth 5YN/A